Telix Pharmaceuticals

Clinical Trial · NCT07197645

A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain

Overview

This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.

Phase

Phase 1

Contacts

Jonathan Roger, MSc

jonathan.roger@telixpharma.com

579-366-1426 ext +1

ClinicalTrials.gov

NCT07197645

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…